Pegylated Interferon Alfa-2b Monotherapy and Pegylated Interferon Alfa-2b plus Lamivudine Combination Therapy for Patients with Hepatitis B Virus E Antigen-Negative Chronic Hepatitis B
Articles > Article · 2007
Authors: Sabahattin Kaymakoglu, Dilek Oguz, Gurden Gur, Selim Gurel, Ethem Tankurt, Galip ERSÖZ, Seren Ozenirler, Cem Kalayci, Sule Poturoglu, Yılmaz Cakaloglu, Atilla Okten
Antimicrobial Agents and Chemotherapy, International, WoS, 2007, vol 51, pp 3020-3022
DOI: 10.1128/aac.00088-07
Summary
Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of <400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.